Form 4: Immix Biopharma CEO Boosts Stake with Share Purchase
Insider Transaction Report
Immix Biopharma's CEO and Chairman, Ilya Rachman, purchased 2,500 shares of common stock at an average price of $2.02 per share, increasing his direct beneficial ownership.
Summary
- Ilya M. Rachman, CEO and Chairman, Director, and a 10% owner of Immix Biopharma, Inc. (IMMX), acquired additional shares.
- The transaction involved the purchase of 2,500 shares of Immix Biopharma Common Stock.
- The shares were acquired on September 17, 2025, at a volume-weighted average price of $2.02 per share.
- Individual purchase prices ranged from $2.01 to $2.02 per share.
- Following this transaction, Ilya Rachman directly beneficially owns 1,140,937 shares of Common Stock.
- The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
Sentiment
Score: 8
Explanation: The sentiment is highly positive due to the CEO and Chairman's direct purchase of company shares, indicating strong insider confidence in Immix Biopharma's future.
Positives
- The CEO and Chairman's purchase of additional shares signals strong confidence in the company's future prospects and valuation.
- The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned purchase and potentially a long-term investment strategy rather than a reactive trade.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance, but the insider purchase implicitly suggests management's positive outlook on the company's future performance.
Management Comments
- Ilya Rachman's decision to purchase additional shares reflects his personal conviction in Immix Biopharma's value and strategic direction.
Industry Context
Insider buying, particularly by a CEO and Chairman, is often interpreted by the market as a strong positive signal, suggesting that management believes the company's stock is undervalued or that significant positive developments are anticipated. This action aligns with a broader trend where insider confidence can influence investor sentiment in the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Transaction Plan Disclosure | The reported transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities. | 09/17/2025 | This indicates a pre-arranged trading plan, which helps mitigate concerns about trading on material non-public information and demonstrates adherence to corporate governance best practices for insider transactions. |
Related Party Transactions
- Ilya M. Rachman, as CEO, Chairman, Director, and a 10% owner, is a related party to Immix Biopharma, Inc. His purchase of company stock is a related party transaction.
Stakeholder Impact
- Shareholders may view this insider purchase as a positive indicator of the company's future performance and value, potentially boosting investor confidence.
- Employees might perceive this as a sign of stability and strong leadership belief in the company's direction.
Key Dates
| Date | Description |
|---|---|
| 09/17/2025 | Date of transaction where Ilya M. Rachman acquired 2,500 shares of Immix Biopharma Common Stock. |
Recommendation
buyThe CEO and Chairman's direct purchase of company shares, especially when executed under a Rule 10b5-1 plan, is a strong signal of insider confidence. This action suggests that management believes the stock is currently undervalued or expects significant positive developments, making it an attractive entry point for investors.
Keywords
Immix Biopharma, IMMX, Insider Buying, CEO Purchase, Stock Acquisition, Ilya Rachman, Form 4, Biopharma, Equity Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.